Johnson & Johnson JNJ rapidly advanced its pipeline in 2025, attaining significant clinical and regulatory milestones that will help drive growth through the back half of the decade. In 2025, it ...

The Delhi High Court has stayed trial court proceedings against Bina Modi and Lalit Bhasin, who were summoned in an assault case filed by Samir Modi. The HC issued notice on their pleas seeking to ...

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill ...

Pediatric patients with moderate to severe hidradenitits suppurativa may now receive secukinumab following new FDA approval for those aged 12 and up.

Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE ...

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a ...

In a groundbreaking milestone for Bangladesh’s fintech industry, aamarPay, a leading payment system operator (PSO), has secured a foreign investment from Simpaisa, a global digital payments ...

Find all the best things to do in Pittsburgh this weekend, from NatureFest to the Pittsburgh Fringe Festival to the Japanese Film Festival.

US FDA approves Novartis Cosentyx for paediatric patients aged 12+ with moderate to severe hidradenitis suppurativa: Basel Monday, March 16, 2026, 14:00 Hrs [IST] Novartis announc ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for moderate-to-severe plaque psoriasis in adults and pediatric ...

Johnson & Johnson (JNJ) on Wednesday announced that the U.S. Food and Drug Administration (FDA) approved Icotyde, a once-daily pill developed with Protagonist Therapeutics (PTGX), as a treatment for ...